Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!
SYNNEX Corporation (NYSE: SNX) stock lost more than 18 percent Monday morning and hit a new 52-week low of $98.68 in reaction to the company's first quarter earnings report. The business process services company reported a top-and-bottom-line beat in its first quarter report but guided its second quarter EPS to be $2.25 to $2.35 versus expectations of $2.41 per share. Revenue was guided to a range of $4.58 to $4.78 billion versus expectations of $4.75 billion.
Sorl Auto Parts, Inc. (NASDAQ: SORL) stock lost nearly 20 percent. The China-based automotive parts maker reported mixed fourth quarter results but guided its full fiscal year 2018 sales to be $450 million which came in ahead of the consensus estimate of $394 million.
Myriad Genetics, Inc. (NASDAQ: MYGN) stock was trading higher by nearly 2 percent. The company said its wholly-owned subsidiary called Myriad Genetic Laboratories received a manufacturing and marketing approval from Japan's government for its BRACAnalysis Diagnostic System.
Compugen Ltd. (NASDAQ: CGEN) stock gained around 9 percent after the therapeutic discovery and development company announced a new agreement with MedImmune for the development of bi-specific and multi-specific immuno-oncology antibody products. As part of the agreement, Compugen will receive a $10 million upfront payment with up to $200 million in other payments tied to royalties on future sales.
MediciNova, Inc. (NASDAQ: MNOV) stock gained 20 percent. The biopharmaceutical company that focuses on developing treatments for unmet medical needs said over the weekend it can terminate a Phase 2 clinical trial of MN-001 in NASH and NAFLD based on " significant positive results from an interim analysis."
New Quarter Begins: Here Are A Few Trends For Investors To Monitor
28 Stocks Moving In Monday's Pre-Market Session
See more from Benzinga
- Why Stifel Remains Bullish On Under Armour After Data Breach
- Alkermes Falls 20% After FDA Refusal To File Letter
- 3 Reasons Why Morgan Stanley Is Bearish On Fitbit
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.